国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
OLANZAPINE (UNII: N7U69T4SZR) (OLANZAPINE - UNII:N7U69T4SZR)
TYA Pharmaceuticals
OLANZAPINE
OLANZAPINE 15 mg
ORAL
PRESCRIPTION DRUG
olanzapine is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents . — Oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one monotherapy maintenance trial deciding among the alternative treatments available for adolescents, clinicians should consider
NDC:64725-0555-1 in a BOTTLE of 30 TABLETS Olanzapine tablets are supplied as follows: 2.5 mg tablets: Yellow, oval shaped uncoated tablets debossed with ‘2.5’ on one side and plain on other side. Bottles of 30’s with Child Resistant Cap …………….…………… NDC 62756-551-83 Bottles of 100’s with Child Resistant Cap …………………….….. NDC 62756-551-88 Bottles of 100’s with Non Child Resistant Cap ….……………….. NDC 62756-551-08 Bottles of 1000’s with Non Child Resistant Cap …………….…… NDC 62756-551-18 5 mg tablets: Yellow, oval shaped uncoated tablets debossed with ‘5’ on one side and plain on other side. Bottles of 30’s with Child Resistant Cap …………….…………… NDC 62756-552-83 Bottles of 100’s with Child Resistant Cap …………………….….. NDC 62756-552-88 Bottles of 100’s with Non Child Resistant Cap….…………….….. NDC 62756-552-08 Bottles of 1000’s with Non Child Resistant Cap……………..…… NDC 62756-552-18 7.5 mg tablets: Yellow, round shaped uncoated tablets debossed with ‘7.5’ on one side and plain on other side. Bottles of 30’s with Child Resistant Cap …………….…………… NDC 62756-553-83 Bottles of 100’s with Child Resistant Cap …………………….….. NDC 62756-553-88 Bottles of 100’s with Non Child Resistant Cap….……….……….. NDC 62756-553-08 Bottles of 1000’s with Non Child Resistant Cap……………..…… NDC 62756-553-18 10 mg tablets: Yellow, oval shaped uncoated tablets debossed with ‘10’ on one side and plain on other side. Bottles of 30’s with Child Resistant Cap …………….…………… NDC 62756-554-83 Bottles of 100’s with Child Resistant Cap …………………….….. NDC 62756-554-88 Bottles of 100’s with Non Child Resistant Cap….…………….….. NDC 62756-554-08 Bottles of 1000’s with Non Child Resistant Cap……………..…… NDC 62756-554-18 15 mg tablets: Yellow, oval shaped uncoated tablets debossed with ‘15’ on one side and plain on other side. Bottles of 30’s with Child Resistant Cap …………….…………… NDC 62756-555-83 Bottles of 100’s with Child Resistant Cap …………………….….. NDC 62756-555-88 Bottles of 100’s with Non Child Resistant Cap….………………... NDC 62756-555-08 Bottles of 1000’s with Non Child Resistant Cap……………..…… NDC 62756-555-18 20 mg tablets: Yellow, oval shaped uncoated tablets debossed with ‘20’ on one side and plain on other side. Bottles of 30’s with Child Resistant Cap …………….…………… NDC 62756-556-83 Bottles of 100’s with Child Resistant Cap …………………….….. NDC 62756-556-88 Bottles of 100’s with Non Child Resistant Cap….…………….….. NDC 62756-556-08 Bottles of 1000’s with Non Child Resistant Cap……………..…… NDC 62756-556-18 Store olanzapine tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses. Protect olanzapine tablets from light and moisture.
Abbreviated New Drug Application
OLANZAPINE - OLANZAPINE TABLET TYA Pharmaceuticals ---------- MEDICATION GUIDE Read the Medication Guide that comes with olanzapine tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or you want to learn more about olanzapine tablets. Olanzapine tablets are not approved for treating psychosis in elderly people with dementia. High blood sugar can happen if you have diabetes already or if you have never had diabetes. High blood sugar could lead to: Your doctor should do tests to check your blood sugar before you start taking olanzapine tablets and during treatment. In people who do not have diabetes, sometimes high blood sugar goes away when olanzapine tablets are stopped. People with diabetes and some people who did not have diabetes before taking olanzapine tablets need to take medicine for high blood sugar even after they stop taking olanzapine tablets. If you have diabetes, follow your doctor’s instructions about how often to check your blood sugar while taking olanzapine tablets. if you have any of these symptoms of high blood sugar (hyperglycemia) while taking olanzapine tablets: High fat levels may happen in people treated with olanzapine tablets, especially in teenagers (13 to 17 years old). You may not have any symptoms, so your doctor should do blood tests to check your cholesterol and triglyceride levels before you start taking olanzapine tablets and during treatment. Weight gain is very common in people who take olanzapine tablets. Teenagers (13 to 17 years old) are more likely to gain weight and to gain more weight than adults. Some people may gain a lot of weight while taking olanzapine tablets, so you and your doctor should check your weight regularly. Talk to your doctor about ways to control weight gain, such as eating a healthy, balanced diet, and exercising. 阅读完整的文件
OLANZAPINE - OLANZAPINE TABLET TYA PHARMACEUTICALS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE OLANZAPINE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR OLANZAPINE TABLETS. OLANZAPINE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1996 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. OLANZAPINE IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (5.1,5.14,17.2) WHEN USING OLANZAPINE AND FLUOXETINE IN COMBINATION, ALSO REFER TO THE SECTION OF THE PACKAGE INSERT FOR SYMBYAX*. BOXED WARNING RECENT MAJOR CHANGES none INDICATIONS AND USAGE Olanzapine is an atypical antipsychotic indicated: _As oral formulation for the:_ Treatment of schizophrenia. ( ) 1.1 Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( ) 14.1 Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( ) 1.2 Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( ) 14.2 Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( ) 1.2 Efficacy was established in two 6-week clinical trials in adults ( ). Maintenance efficacy has not been systematically evaluated. 14.2 _As Olanzapine and Fluoxetine in Combination for the:_ Treatment of depressive episodes associated with bipolar I disorder. ( ) 1.5 Efficacy was established with Symbyax* (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax*. DOSAGE AND ADMINISTRATION Schizophrenia in adults ( ) 2.1 Oral: Start at 5 mg to 10 m 阅读完整的文件